Table 1.

Baseline demographics and clinical characteristics for all patients with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) measurements available.

Variable	All patients				Missing at follow-up				Follow-up
	N	Median	Q1	Q3	N	Median	Q1	Q3	N	Median	Q1	Q3
Age, years	108	59.5	50.7	67.1	33	59.3	44	67.9	75	59.7	51.5	66.0
Disease duration, years	108	7.3	3.3	13.9	33	8.5	4	17	75	6	3.1	13
PhGH assessment VAS, mm	86	35.5	27	55	25	35	27	47	61	37	27	61
Tender joints, 0–28	108	10	4	18	33	8	2	19	75	11	4	18
Swollen joints, 0–28	108	7	2	12	33	6	2	11	75	8	3	12
PtGH assessment VAS, mm	108	67	46	79	33	69	51	81	75	64	41	79
CRP, mg/L	108	10	2.7	30.5	33	10.7	3.9	29.9	75	11.1	2.5	34.9
ESR, mm/h	108	25	12	44	33	19	11	37	75	25	12	47
DAS28-CRP, 0–9.4	108	5.09	4.09	6.12	33	4.97	3.85	6.00	75	5.25	4.17	6.17
DAS28-ESR, 0–9.4	108	5.64	4.24	6.56	33	5.35	4.33	5.95	75	5.75	4.50	6.56
		Number subgroup	%	N/A		Number subgroup	%	N/A		Number subgroup	%	N/A
Gender, males, %	108	31	29		33	11	33		75	20	27
Etanercept	108	30	28		33	6	18		75	24	32
Adalimumab	108	61	56		33	20	61		75	41	55
Infliximab	108	17	16		33	7	21		75	10	13
Methotrexate	101*	65	64		30	18	60		71	47	66
Prednisolone	101*	46	46		30	14	47		71	32	45
Salazopyrin	101*	29	29		30	5	17		71	24	34

PhGH assessment = physician assessment of general health, VAS = Visual Analogue Scale, PtGH = patient assessment of general health, DAS28 = Disease Activity Score, Q1 and Q3 = first and third quartile. ^*There was only information on other medicine uses for 101/108 participants.